1- (1- (2- amino- pyridin- 4- ylmethyl)- 1H- indol- 4- yl)- 3- (5- bromo- 2- methoxyphenyl)urea

JI-101 is the HCl salt; has antineoplastic activity; structure in first source

Also Known As:

JI 101; JI-101; JI101 cpd

Networked: 4 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - 1-(1-(2-amino-pyridin-4-ylmethyl)-1H-indol-4-yl)-3-(5-bromo-2-methoxyphenyl)urea: 4
Organic Chemicals: 133
- Amides: 2428
  - Urea: 15015
    - Phenylurea Compounds: 1
      - 1-(1-(2-amino-pyridin-4-ylmethyl)-1H-indol-4-yl)-3-(5-bromo-2-methoxyphenyl)urea: 4
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Phenylurea Compounds: 1
        1-(1-(2-amino-pyridin-4-ylmethyl)-1H-indol-4-yl)-3-(5-bromo-2-methoxyphenyl)urea: 4

Experts

1.	Mullangi, Ramesh: 2 articles (02/2012 - 07/2011)
2.	Srinivas, Nuggehally R: 2 articles (02/2012 - 07/2011)
3.	Agarwal, Neeraj: 1 article (12/2015)
4.	Boucher, Kenneth: 1 article (12/2015)
5.	Luebke, Aaron: 1 article (12/2015)
6.	Patel, Jesal: 1 article (12/2015)
7.	Sharma, Sunil: 1 article (12/2015)
8.	Wade, Mark L: 1 article (12/2015)
9.	Werner, Theresa L: 1 article (12/2015)
10.	Benjamin, Biju: 1 article (02/2012)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2015 - "This was the first clinical study assessing anti-tumor activity of JI-101 in a combinatorial regimen. " 02/01/2012 - "This method has been successfully applied for the characterization of JI-101 pharmacokinetics in cancer patients." 07/01/2011 - "Highly sensitive method for the determination of a novel triple kinase inhibitor with anti-cancer activity, JI-101, in rat plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study." 12/01/2015 - "We conducted a pilot trial to assess the pharmacokinetics (PK), tolerability, and efficacy of JI-101 in combination with everolimus in advanced cancers, and pharmacodynamics (PD), tolerability, and efficacy of JI-101 in ovarian cancer. " 01/01/2012 - "JI-101, chemically 1-[1-(2-amino-pyridin-4-ylmethyl)-1H-indol-4-yl]-3-(5-bromo-2-methoxy-phenyl)-urea hydrochloride, is a novel orally active kinase inhibitor, which has shown potent in vitro and in vivo anticancer activity against a variety of cancer cell lines and xenografts. "
2.	Ovarian Neoplasms (Ovarian Cancer) 12/01/2015 - "The novel mechanism of action of JI-101 is promising in ovarian cancer treatment and further prospective studies of this agent may be pursued in a less refractory patient population or in combination with cytotoxic chemotherapy." 12/01/2015 - "We conducted a pilot trial to assess the pharmacokinetics (PK), tolerability, and efficacy of JI-101 in combination with everolimus in advanced cancers, and pharmacodynamics (PD), tolerability, and efficacy of JI-101 in ovarian cancer. " 12/01/2015 - "A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort."

Related Drugs and Biologics

1.	Everolimus
2.	Phosphotransferases (Kinase)
3.	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
4.	Urea (Carbamide)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)